Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | APP | P05067 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26020287 | 0.87 | HSD17B10 (0.34) | ALDH1A1KDM4ESMN1; SMN2CYP1A2CYP2C19 | |
| SCHEMBL25934600 | 0.85 | HSD17B10 (0.34) | ALDH1A1KDM4ESMN1; SMN2CYP1A2CYP2C19 | |
| SCHEMBL26020502 | 0.84 | CYP1A2 (0.34) | ALDH1A1KDM4ESMN1; SMN2CYP1A2CYP2C19 | |
| SCHEMBL26412177 | 0.84 | APP (0.30) | APPMAPT | |
| SCHEMBL26412339 | 0.82 | HSD17B10 (0.34) | ALDH1A1KDM4ESMN1; SMN2CYP1A2CYP2C19 | |
| SCHEMBL26412453 | 0.81 | CYP1A2 (0.33) | CYP1A2CYP2C19HSD17B10NPC1POLB | |
| SCHEMBL26412172 | 0.76 | PTGER4 (0.31) | ALDH1A1 | |
| SCHEMBL26020290 | 0.70 | APP (0.32) | APPMAPT | |
| SCHEMBL26412165 | 0.69 | PTPN11 (0.40) | ALDH1A1KDM4ECYP1A2HSD17B10HPGD | |
| SCHEMBL26412167 | 0.68 | CYP4F2 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230130109-A1 | MACROCYCLIC INDOLE DERIVATIVES AS INHIBITORS OF MCL-1 | JANSSEN PHARMACEUTICA NV (BE) | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230130109-A1 | MACROCYCLIC INDOLE DERIVATIVES AS INHIBITORS OF MCL-1 | MCL1, BCL2L1, BAK1 | ALDH1A1 1067/4885KDM4E 1710/4885SMN1; SMN2 2915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.